NEO News and Press, NeoGenomics Inc.

We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of ...

2026-02-17 12:56:17 ET More on NeoGenomics NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript NeoGenomics, Inc. 2025 Q4 - Results - Earnings Call Presentation NeoGenomics: Distribution Moat In Community Oncology NeoGenomics Non-GAAP EPS of $0.06 beats b...

2026-02-17 12:55:13 ET NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call February 17, 2026 8:30 AM EST Company Participants Kendra Sweeney - Vice President of Investor Relations & Communications Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Of...

2026-02-17 10:17:05 ET Image source: The Motley Fool. Tuesday, Feb. 17, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-17 07:08:32 ET More on NeoGenomics NeoGenomics: Distribution Moat In Community Oncology NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Confere...

Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading provider of oncology diag...

Iamgold Corporation (IAG) is expected to report $0.55 for Q4 2025 Bel Fuse Inc (BELFB) is expected to report $1.44 for Q4 2025 Beta Bionics Inc. (BBNX) is expected to report $-0.42 for Q4 2025 TPG RE Finance Trust Inc. (TRTX) is expected to report $0.25 for Q4 2025 CEVA Inc. (CEVA...

2026-02-13 10:40:13 ET More on NeoGenomics NeoGenomics: Distribution Moat In Community Oncology NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Confere...

New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable pre...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company...